Scarica l'app Stockscreener
1.005
3.37%
-0.035
Precedente Chiudi:
$1.04
Aprire:
$1.07
Volume 24 ore:
110.61K
Relative Volume:
0.36
Capitalizzazione di mercato:
$21.68M
Reddito:
-
Utile/perdita netta:
$-8.29M
Rapporto P/E:
-1.4357
EPS:
-0.7
Flusso di cassa netto:
$-6.47M
1 W Prestazione:
+8.06%
1M Prestazione:
-14.83%
6M Prestazione:
-30.21%
1 anno Prestazione:
-26.64%
Intervallo 1D:
$0.99
$1.07
Intervallo di 1 settimana:
$0.927
$1.07
Portata 52W:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.005 | 22.43M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.68 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.42 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
845.74 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.99 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
356.56 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | Alliance Global Partners | Buy |
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
NanoViricides advances toward fully funded Phase II MPox trial in DRC - Proactive financial news
NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Proactive financial news
NanoViricides: Fiscal Q2 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Second Quarter Earnings Overview - Bitget
Moving Averages: Is NanoViricides Inc exposed to political riskJuly 2025 Movers & Growth Focused Stock Reports - baoquankhu1.vn
Can NanoViricides Inc grow without external fundingJuly 2025 Review & Growth Focused Stock Reports - baoquankhu1.vn
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news
NanoViricides seeks FDA orphan status for MPox drug - Proactive financial news
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget
New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Ventura County Star
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - USA Today
NanoViricides seeks orphan drug status with US FDA for measles treatment - Yahoo Finance
Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today
Trading Recap: Is NanoViricides Inc part of any ETFJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - baoquankhu1.vn
CEO Change: Is NanoViricides Inc undervalued by DCF analysisWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Reno Gazette Journal
NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Phase II Trial for MPox Treatment - citybuzz -
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - accessnewswire.com
Can NanoViricides Inc. continue delivering strong returnsJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Can NanoViricides Inc continue delivering strong returnsQuarterly Growth Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - Hattiesburg American
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference - chronicle-tribune.com
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - hattiesburgamerican.com
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Hattiesburg American
ETF Watch: Should I hold or sell NanoViricides Inc nowJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Aug Momentum: Is NanoViricides Inc forming a bullish divergenceTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Support Test: Should I invest in NanoViricides Inc before earningsJuly 2025 PostEarnings & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Jobs Data: How much upside does NanoViricides Inc have2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
NanoViricides Highlights Need for Broad-Spectrum Antivirals During Severe Influenza Season - citybuzz -
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
1.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):